Engineered immune cells take aim at tough lymphomas in first human test

NCT ID NCT03602157

Ongoing Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack cancer cells carrying the CD30 protein. Some of these cells are also engineered to produce CCR4, a protein that helps guide them to the tumor. The main goal is to find a safe dose and understand side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Genetically modified T cells (CAR T-cells) targeting CD30, with or without added CCR4 protein
What this could lead to: If successful, this could lead to a new treatment option for patients with hard-to-treat lymphomas that have not responded to standard therapies.
What could go wrong: This is an early Phase 1 trial with only 43 participants, focused on safety and dosing. It is too soon to know if the treatment will work, and there are risks of side effects like cytokine release syndrome or nerve toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma classic Hodgkin lymphoma immune system disorder immunoproliferative disorder lymphatic system disorder lymphoma lymphomatoid papulosis lymphoproliferative syndrome mycosis fungoides neoplasm primary cutaneous anaplastic large cell lymphoma primary cutaneous lymphoma primary cutaneous T-cell non-Hodgkin lymphoma Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA CUTANEOUS LYMPHOMA CUTANEOUS T-CELL LYMPHOMA GRAY ZONE LYMPHOMA IMMUNE SYSTEM DISEASES IMMUNOPROLIFERATIVE DISORDERS LYMPHATIC DISEASES LYMPHOMA LYMPHOMATOID PAPULOSIS LYMPHOPROLIFERATIVE DISORDERS MYCOSIS FUNGOIDES NEOPLASMS SEZARY SYNDROME

Contacts and locations

Locations

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.